Skip to main content Accessibility help
×
Hostname: page-component-84b7d79bbc-tsvsl Total loading time: 0 Render date: 2024-07-25T22:30:05.080Z Has data issue: false hasContentIssue false

141 - Topiramate

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Topamax, Topamax Sprinkle, Trokendi XR, Qudexy XR

Generic?

• Yes

Class

• Antiepileptic drug (AED)

Commonly Prescribed for

(FDA approved in bold)

Partial-onset seizures (adjunctive; adults and pediatric patients age 2–16)

Primary generalized tonic-clonic seizures (adjunctive; adults and pediatric patients age 2–16)

Lennox-Gastaut syndrome adjunctive therapy (age > 2)

Migraine prophylaxis (Topamax only)

• Cluster headache prophylaxis

• Myoclonic epilepsy

• Neuralgia/neuropathic pain

• Drop attacks associated with Lennox- Gastaut syndrome

• Obesity

• Bipolar disorder

• Binge-eating disorder/bulimia

• Idiopathic intracranial hypertension

• Alcohol dependence

• Essential tremor

• Phantom limb pain

How the Drug Works

There are multiple mechanisms of action, and it is uncertain which of these give the drug its effectiveness

• Augments the GABAA1 receptor

• Blocks voltage-dependent sodium and calcium (N-type) channels

• Antagonizes the glutamate receptor (AMPA/ kainate subtype)

• Inhibits carbonic anhydrase (isoenzymes II and IV)

• May inhibit protein kinase activity

• Possible serotonin activity on 5-HT2C receptor

How Long Until It Works

• Seizures: may decrease by 2 weeks

• Migraines: may decrease in as little as 2 weeks, but can take up to 3 months on a stable dose to see full effect

If It Works

• Seizures: goal is the remission of seizures. Continue as long as effective and well tolerated. Consider tapering slowly, stopping after 2 years without seizures, depending on the type of epilepsy

• Migraine: goal is a 50% or greater reduction in migraine disability. Consider tapering or stopping if headaches remit for more than 6 months or if considering pregnancy

If It Doesn't Work

• Increase to highest tolerated dose

• Epilepsy: consider changing to another agent, adding a second agent, using a medical device, or a referral for epilepsy surgery evaluation. When adding a second agent, keep drug interactions in mind

• Migraine: address other issues, such as medication overuse, other coexisting medical disorders, such as anxiety, and consider changing to another agent or adding a second agent

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 517 - 521
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Topiramate
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.142
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Topiramate
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.142
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Topiramate
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.142
Available formats
×